Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks Licensing Deal with RiboTask

NEW YORK (GenomeWeb News) – Reagents maker Link Technologies said today that it will sell RiboTask's nucleic acid monomers, under a new license agreement.

Link, a Scottish company, will make and commercialize RiboTask's unlocked-nucleic acid (UNA) monomer phosphoramadite reagents, which are used to enable fine-tuning of oligonucleotide stability in siRNA gene silencing and other applications.

Patents for the therapeutic use of UNA oligonucleotides are held by MDRNA, according to Link.

Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.